This is the authors' abstract. We don't add key points for this paper.
Drugs represent unique commodities whose value is determined not only by their therapeutic efficacy but also by their commercial performance. This perspective presents an analysis of the top 20 small-molecule neurology drugs with the highest global retail sales in 2024. These medications not only provide therapeutic benefits to patients and improve their life quality but also generate significant revenue for the pharmaceutical companies that have invested in their development. We examine each drug's approved indications, sales performance, and the factors that contribute to their excellence in the field of neurology. Furthermore, from a medicinal chemistry perspective, key aspects of their design or origins, pharmacology, and synthesis are presented, aiming to offer a comprehensive understanding of the discovery and commercial successes of these blockbuster drugs, thereby fostering the development of more novel therapeutic treatments for neurological disorders.
Answers are grounded in this paper and cite their sources.
No takes yet. Share an insight, caveat, or question.
Huang et al. (2026) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: